0001460702
false
0001460702
2023-08-15
2023-08-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 15, 2023
Qualigen
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-37428 |
|
26-3474527 |
| (State
or other jurisdiction |
|
(Commission |
|
(I.R.S.
Employer |
| of
incorporation) |
|
File
Number) |
|
Identification
No.) |
2042
Corte Del Nogal, Carlsbad, California 92011
(Address
of principal executive offices) (Zip Code)
(760)
918-9165
(Registrant’s
telephone number, including area code)
n/a
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
| Common
Stock, par value $.001 per share |
|
QLGN |
|
The
Nasdaq Capital Market of The Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (§230.405 of this
chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Item
2.02 Results of Operations and Financial Condition.
On
August 15, 2023, Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the
Company’s financial results for the quarter ended June 30, 2023. A copy of this press release is furnished as Exhibit 99.1 and
is incorporated herein by reference.
The
information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
QUALIGEN
THERAPEUTICS, INC. |
| |
|
|
| Date:
August 15, 2023 |
By: |
/s/
Michael S. Poirier |
| |
|
Michael
S. Poirier, Chief Executive Officer |
Exhibit
99.1
Qualigen
Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
Investigational
New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company
Company
divests FastPack® diagnostics business for approximately $5 million in all cash transaction to support advancement of therapeutics
pipeline
CARLSBAD,
Calif., Aug. 15th, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics
company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces
financial results for the second quarter ending June 30, 2023, and provides a corporate update:
Highlights
For Second Quarter and To Date 2023:
Therapeutics
Highlights:
QN-302
| ● | Received
US FDA clearance to initiate Phase 1 clinical trial of QN-302 for treatment of advanced or
metastatic solid tumors |
| ● | Presented
four posters at the American Association for Cancer Research (AACR) Annual Meeting, in April
2023: |
| ○ | “A
comparison of the activity of the quadruplex-targeting experimental drugs QN-302 and CX-5461
(Pidnarulex) in wild-type and gemcitabine-resistant pancreatic cancer cell lines” Ahmed
Ahmed, Tariq Arshad, and Stephen Neidle (Poster) |
| ○ | “The
potent quadruplex-binding compound QN-302 down-regulates the S100P gene in vitro and in vivo
models of pancreatic cancer: a potential therapeutic target and biomarker for PDAC”
Nicole Williams, Jenny Worthington, Ahmed Ahmed, Tariq Arshad, and Stephen Neidle (Poster) |
| ○ | “The
potent quadruplex-binding compound QN-302 shows anti-tumor activity as a monotherapy in an
orthotopic in vivo model of pancreatic cancer” Nicole Williams, Danielle Santos, Jenny
Worthington, Ahmed Ahmed, Tariq Arshad and Stephen Neidle (Poster) |
| ○ | “Structure-based
design rules for potent quadruplex-binding compounds based on the naphthalene diimide core”
Stephen Neidle (Poster) |
Pan-RAS
| ● | Presented
data at the American Society of Clinical Oncology (ASCO) Annual Meeting, in June 2023: |
| ○ | “Impact
of novel pan-RAS inhibitors on efficacy and resistance to AMG-510 and MRTX-1133 in pancreatic
cancer cell lines.” Howard Donninger, Rachel Ferrill, Becca Von Baby, Joe Burlison,
John O. Trent, Michael Sabo, Tariq Arshad, Geoffrey J. Clark (Poster) |
| ○ | “A
novel pan-RAS inhibitor for luminal B breast cancer.” Tariq Arshad, Howard Donninger,
Mike Sabo, John Trent, Geoffrey J. Clark, Joe Burlison. This abstract can be found in the
ASCO 2023 Annual Meeting Abstract Book (Abstract) |
QN-247
| ● | Presented
one poster at the American Association for Cancer Research (AACR) Annual Meeting, in April
2023: |
| ○ | “Nano-immunotherapy:
Efficacy of nanoconjugate QN-247 in a Triple Negative Breast Cancer (TNBC) mouse model”
Tariq Arshad, Stephen Fait, Guy Gammon, Andrew Hertig, Mark J. Sarno (Poster) |
Diagnostics
Highlights:
| ● | Sold
FastPack® diagnostics business to Chembio Diagnostics, Inc., an American subsidiary
of French diagnostics provider BIOSYNEX Group, a leader in the design and distribution of
rapid tests |
| ● | Amended
our Master Funding Agreement with NanoSynex to substantially reduce or eliminate Qualigen’s
future cash funding obligations |
Michael
Poirier, Qualigen’s Chairman and CEO commented, “2023 has been a transformative year for Qualigen Therapeutics. Despite continued
industry headwinds, we significantly advanced our oncology-focused pipeline within budget and timelines. To build on our momentum, the
company recently achieved two major milestones: We received US FDA Investigational New Drug (IND) clearance to initiate a Phase 1 clinical
trial for QN-302, a small molecule G-Quadruplex (G4)-selective transcription inhibitor for treatment of advanced or metastatic solid
tumors, and we divested our FastPack® diagnostics business.”
“On
August 1st we received news that the FDA cleared the Company’s IND application for QN-302. Based on this clearance,
the Company plans to initiate the Phase 1 clinical trial in the second half of 2023 and will enroll patients with advanced or metastatic
solid tumors. This clearance is the culmination of dedicated efforts by the Qualigen team and our extensive network of collaborators,
subject matter experts, and service providers and exemplifies our steadfast commitment to patients.
The
proposed Phase 1 trial is a multicenter, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamic study with dose expansion
to evaluate safety, tolerability, and antitumor activity of QN-302 in patients with advanced solid tumors that have not responded to
or have recurred following treatment with available therapies. The Company anticipates dosing of at least 24 patients in the Phase 1
trial can be completed in 2024.”
“In
July we divested our FastPack® diagnostics business to Chembio Diagnostics, Inc., an American subsidiary of French diagnostics provider
BIOSYNEX Group for [give price, including amount received at closing, escrow amount and timing of escrow release]. We are proud of the
legacy our FastPack® rapid immunodiagnostics system has established by providing patients and doctors with high quality
laboratory solutions for over two decades. This all-cash sale enhances our business focus while providing additional capital for our
therapeutics pipeline, in particular our clinical-stage QN-302 program and our preclinical Pan-RAS inhibitor platform. Going forward,
we will maintain streamlined operations that will reduce overhead expenses as an out-sourced virtual model.”
“In
parallel with QN-302 clinical development, we continue to advance compounds within our Pan-RAS therapeutic platform. We are on track
to identify a late in vivo stage candidate by the end of the year, which we will advance into IND-enabling studies by 2024. We are very
encouraged by the interest we received at the ASCO Annual Meeting this June regarding our poster presentation on the impact of novel
pan-RAS inhibitors on efficacy and resistance to AMG-510 and MRTX-1133 in pancreatic cancer cell lines. We believe a pan-RAS approach
may overcome KRAS G12C resistance that effects depth and duration of responses in current offerings, and we will continue to build our
data package with our collaborators in the second half of this year.”
“We
are looking forward to initiating our Phase 1 clinical trial of QN-302 in the second half of this year and potentially providing a treatment
option in the future to patients who have not responded to or have relapsed following treatment with available therapies. Along with
the encouraging data presented on our Pan-RAS platform, our therapeutics direction is taking shape, and is an exciting time for Qualigen
and our stakeholders,” concluded Mr. Poirier.
Financial
Highlights
Revenues
from product sales for the quarter ended June 30, 2023 were approximately $1.6 million compared to approximately $1.4 million for the
same period of 2022, an increase of $0.2 million or 14%, due to growth in sales volumes and higher average unit selling prices. Cost
of product sales were $1.0 million, or 62% of product sales, compared to $1.1 million, or 77% of product sales for the same period of
2022. The improvement was primarily due to a reduction in force implemented in January 2023.
General
and administrative expenses remained at $2.7 million for the quarter, compared to the same period of 2022.
Research
and development costs decreased from $1.5 million for the three months ended June 30, 2022 to $1.3 million for the three months ended
June 30, 2023. Of the $1.3 million of research and development costs for the three months ended June 30, 2023, approximately $1.2 million
(89%) was attributable to therapeutics and $0.2 million (11%) was attributable to diagnostics. Of the $1.5 million of research and development
costs for the three months ended June 30, 2022, $1.1 million (73%) was attributable to therapeutics and $0.4 million (27%) was attributable
to diagnostics.
The
$0.1 million increase in therapeutics research and development costs was primarily due to a $0.5 million increase in QN-302 pre-clinical
research and development costs, offset by a decrease of pre-clinical research and development costs of $0.4 million for QN-247. The $0.2
million decrease in diagnostics research and development costs was primarily due to a $0.2 million decrease in stock-based compensation
expense and a $0.1 million decrease in payroll expenses related to FastPack due to the January 2023 reduction in force, offset by an
increase of $0.1 million in research and development expenses for NanoSynex.
Sales
and marketing expenses were approximately $0.2 million for the quarter ended June 30, 2023, a decrease of $0.1 million or 45%, compared
to the quarter ended June 30, 2022, primarily due to the January 2023 reduction in force.
For
the quarter ended June 30, 2023, the Company reported a net loss attributable to Qualigen Therapeutics, Inc. of approximately $3.5 million,
or $0.69 per common share basic and diluted, compared to a net loss of approximately $4.1 million, or $1.12 per common share basic and
diluted, for the corresponding period in 2022.
About
Qualigen Therapeutics, Inc.
Qualigen
Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. Our investigational
QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells;
such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation. The investigational
compounds within Qualigen’s family of Pan-RAS oncogene protein-protein interaction inhibitor small molecules are believed to inhibit
or block the binding of mutated RAS genes’ proteins to their effector proteins, thereby leaving the proteins from the mutated RAS
unable to cause further harm. In theory, such mechanism of action may be effective in the treatment of about one quarter of all cancers,
including certain forms of pancreatic, colorectal, and lung cancers.
Forward-Looking
Statements
This
news release contains forward-looking statements by Qualigen that involve risks and uncertainties and reflect the Company’s judgment
as of the date of this release. These statements include those related to the Company’s prospects and strategy for development
of its therapeutic drug candidates, including the anticipated timeline for initiating the Company’s Phase 1 clinical trial and
enrolling and dosing of patients and the identification of a late in vivo candidate. Actual events or results may differ from the Company’s
expectations. There can be no assurance that the Company will be able to successfully develop any drugs (including QN-302, Pan-RAS and
QN-247); that preclinical development of the Company’s drugs (including Pan-RAS and QN-247) will be completed on any projected
timeline or will be successful; that any clinical trials will be approved to begin by or will proceed as contemplated by any projected
timeline, or at all; that any future clinical trial data will be favorable or that such trials will confirm any improvements over other
products or lack negative impacts; that any drugs will receive required regulatory approvals (or Fast Track designation or Orphan Drug
status) or that they will be commercially successful; that patents will issue on the Company’s owned and in-licensed patent applications;
that such patents, if any, and the Company’s currently owned and in-licensed patents would prevent competition; or that the Company
will be able to procure or earn sufficient working capital to complete the development, testing and launch of the Company’s prospective
therapeutic products (including QN-302, Pan-RAS and QN-247). The Company’s stock price could be harmed if any of the events or
trends contemplated by the forward-looking statements fail to occur or is delayed or if any actual future event otherwise differs from
expectations. Additional information concerning these and other risk factors affecting the Company’s business can be found in the
Company’s prior filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K, all
of which are available at www.sec.gov.
The
Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as
required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
For
more information about Qualigen Therapeutics, Inc., please visit www.qlgntx.com.
Contact:
Investor
Relations
760-530-6487
ir@qlgntx.com.
Source:
Qualigen Therapeutics, Inc.
QUALIGEN
THERAPEUTICS, INC.
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE LOSS
(Unaudited)
| | |
For the Three Months Ended
June 30, | | |
For the Six Months Ended
June 30, | |
| | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| REVENUES | |
| | | |
| | | |
| | | |
| | |
| Net product sales | |
$ | 1,627,031 | | |
$ | 1,430,534 | | |
$ | 3,234,201 | | |
$ | 2,152,563 | |
| Total revenues | |
| 1,627,031 | | |
| 1,430,534 | | |
| 3,234,201 | | |
| 2,152,563 | |
| | |
| | | |
| | | |
| | | |
| | |
| EXPENSES | |
| | | |
| | | |
| | | |
| | |
| Cost of product sales | |
| 1,016,542 | | |
| 1,099,677 | | |
| 2,281,368 | | |
| 1,928,524 | |
| General and administrative | |
| 2,665,849 | | |
| 2,660,857 | | |
| 4,380,283 | | |
| 5,559,608 | |
| Research and development | |
| 1,326,544 | | |
| 1,506,227 | | |
| 3,448,095 | | |
| 3,370,972 | |
| Sales and marketing | |
| 169,223 | | |
| 305,103 | | |
| 368,337 | | |
| 443,426 | |
| Total expenses | |
| 5,178,158 | | |
| 5,571,864 | | |
| 10,478,083 | | |
| 11,302,530 | |
| | |
| | | |
| | | |
| | | |
| | |
| LOSS FROM OPERATIONS | |
| (3,551,127 | ) | |
| (4,141,330 | ) | |
| (7,243,882 | ) | |
| (9,149,967 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| OTHER EXPENSE (INCOME), NET | |
| | | |
| | | |
| | | |
| | |
| Gain on change in fair value of warrant liabilities | |
| (440,294 | ) | |
| (14,800 | ) | |
| (1,478,967 | ) | |
| (698,042 | ) |
| Interest expense (income), net | |
| 377,416 | | |
| (4,824 | ) | |
| 921,652 | | |
| (11,132 | ) |
| Loss on voluntary conversion of convertible debt | |
| — | | |
| — | | |
| 1,077,287 | | |
| — | |
| Loss on disposal of equipment held for lease | |
| 63,302 | | |
| — | | |
| 63,302 | | |
| — | |
| Other income, net | |
| (5,680 | ) | |
| 376 | | |
| (10,559 | ) | |
| 341 | |
| Loss on fixed asset disposal | |
| — | | |
| — | | |
| 300 | | |
| — | |
| Total other expense (income), net | |
| (5,256 | ) | |
| (19,248 | ) | |
| 573,015 | | |
| (708,833 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES | |
| (3,545,871 | ) | |
| (4,122,082 | ) | |
| (7,816,897 | ) | |
| (8,441,134 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| (BENEFIT) PROVISION FOR INCOME TAXES | |
| (38,182 | ) | |
| 5,438 | | |
| (201,959 | ) | |
| 6,173 | |
| | |
| | | |
| | | |
| | | |
| | |
| NET LOSS | |
| (3,507,689 | ) | |
| (4,127,520 | ) | |
| (7,614,938 | ) | |
| (8,447,307 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net loss attributable to noncontrolling interest | |
| (43,484 | ) | |
| (4,116 | ) | |
| (304,512 | ) | |
| (4,116 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net loss attributable to Qualigen Therapeutics, Inc. | |
$ | (3,464,205 | ) | |
$ | (4,123,404 | ) | |
$ | (7,310,426 | ) | |
$ | (8,443,191 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net loss per common share, basic and diluted | |
$ | (0.69 | ) | |
$ | (1.12 | ) | |
$ | (1.46 | ) | |
$ | (2.35 | ) |
| Net loss per common share, basic | |
$ | (0.69 | ) | |
$ | (1.12 | ) | |
$ | (1.46 | ) | |
$ | (2.35 | ) |
| Weighted—average number of shares outstanding, basic and diluted | |
| 5,052,463 | | |
| 3,668,016 | | |
| 5,006,050 | | |
| 3,599,093 | |
| Weighted—average number of shares outstanding, basic | |
| 5,052,463 | | |
| 3,668,016 | | |
| 5,006,050 | | |
| 3,599,093 | |
| | |
| | | |
| | | |
| | | |
| | |
| Other comprehensive loss, net of tax | |
| | | |
| | | |
| | | |
| | |
| Net loss | |
$ | (3,507,689 | ) | |
$ | (4,127,520 | ) | |
$ | (7,614,938 | ) | |
$ | (8,447,307 | ) |
| Foreign currency translation adjustment | |
| (56,747 | ) | |
| 65,540 | | |
| 119,473 | | |
| 65,540 | |
| Other comprehensive loss | |
| (3,564,436 | ) | |
| (4,061,980 | ) | |
| (7,495,465 | ) | |
| (8,381,767 | ) |
| Comprehensive loss attributable to noncontrolling interest | |
| (43,484 | ) | |
| (4,116 | ) | |
| (304,512 | ) | |
| (4,116 | ) |
| Comprehensive loss attributable to Qualigen Therapeutics, Inc. | |
$ | (3,520,952 | ) | |
$ | (4,057,864 | ) | |
$ | (7,190,953 | ) | |
$ | (8,377,651 | ) |
The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
QUALIGEN
THERAPEUTICS, INC.
CONDENSED
CONSOLIDATED BALANCE SHEETS
(Unaudited)
| | |
June 30, 2023 | | |
December 31, 2022 | |
| ASSETS | |
| | | |
| | |
| Current assets | |
| | | |
| | |
| Cash | |
$ | 1,341,659 | | |
$ | 7,034,434 | |
| Accounts receivable, net | |
| 679,380 | | |
| 538,587 | |
| Inventory, net | |
| 1,563,399 | | |
| 1,586,297 | |
| Prepaid expenses and other current assets | |
| 1,278,077 | | |
| 1,661,220 | |
| Total current assets | |
| 4,862,515 | | |
| 10,820,538 | |
| Restricted cash | |
| 5,434 | | |
| 5,690 | |
| Right-of-use assets | |
| 1,305,970 | | |
| 1,422,538 | |
| Property and equipment, net | |
| 498,647 | | |
| 345,087 | |
| Intangible assets, net | |
| 5,833,070 | | |
| 5,845,702 | |
| Goodwill | |
| 625,602 | | |
| 625,602 | |
| Other assets | |
| 18,334 | | |
| 18,334 | |
| Total Assets | |
$ | 13,149,572 | | |
$ | 19,083,491 | |
| | |
| | | |
| | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
| Current liabilities | |
| | | |
| | |
| Accounts payable | |
$ | 1,756,183 | | |
$ | 857,311 | |
| Accrued vacation | |
| 332,617 | | |
| 467,948 | |
| Accrued expenses and other current liabilities | |
| 1,980,555 | | |
| 1,511,856 | |
| R&D grant liability | |
| 151,620 | | |
| 780,682 | |
| Deferred revenue, current portion | |
| 94,474 | | |
| 116,161 | |
| Operating lease liability, current portion | |
| 257,155 | | |
| 240,645 | |
| Short term debt-related party | |
| 965,155 | | |
| 950,722 | |
| Warrant liabilities | |
| 133,500 | | |
| 788,100 | |
| Warrant liabilities - related party | |
| 2,010,180 | | |
| 2,834,547 | |
| Convertible debt - related party | |
| 812,419 | | |
| 60,197 | |
| Total current liabilities | |
| 8,493,859 | | |
| 8,608,170 | |
| Operating lease liability, net of current portion | |
| 1,168,653 | | |
| 1,301,919 | |
| Deferred revenue, net of current portion | |
| 28,648 | | |
| 49,056 | |
| Deferred tax liability | |
| 150,369 | | |
| 357,757 | |
| Total liabilities | |
| 9,841,528 | | |
| 10,316,901 | |
| Commitments and Contingencies (Note 12) | |
| - | | |
| - | |
| Stockholders’ equity | |
| | | |
| | |
| Qualigen Therapeutics, Inc. stockholders’ equity: | |
| | | |
| | |
| Common stock, $0.001 par value; 225,000,000 shares authorized; 5,052,463 and 4,210,737 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | |
| 42,952 | | |
| 42,110 | |
| Additional paid-in capital | |
| 112,554,830 | | |
| 110,528,050 | |
| Accumulated other comprehensive income | |
| 131,891 | | |
| 50,721 | |
| Accumulated deficit | |
| (110,695,598 | ) | |
| (103,385,172 | ) |
| Total Qualigen Therapeutics, Inc. stockholders’ equity | |
| 2,034,075 | | |
| 7,235,709 | |
| Noncontrolling interest | |
| 1,273,969 | | |
| 1,530,881 | |
| Total Stockholders’ Equity | |
| 3,308,044 | | |
| 8,766,590 | |
| Total Liabilities & Stockholders’ Equity | |
$ | 13,149,572 | | |
$ | 19,083,491 | |
The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
v3.23.2
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
